Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss attributable to AgeX	$ (10,865)	$ (12,154)
Net loss attributable to noncontrolling interest	(111)	(230)
Adjustments to reconcile net loss attributable to AgeX to net cash used in operating activities:
Gain on sale of equity method investment in Ascendance		(354)
Depreciation expense	699	91
Amortization of intangible assets	559	558
Amortization of right-of-use asset	424	302
Amortization of debt issuance cost	487	54
Stock-based compensation	933	1,907
Foreign currency remeasurement gain and other	119	76
Changes in operating assets and liabilities:
Accounts and grant receivables, net	10	(232)
Prepaid expenses and other current assets	839	473
Accounts payable and accrued liabilities	340	169
Related party payables	15	(68)
Insurance premium liability	(713)	(599)
Deferred revenues	57	(34)
Other current liabilities	(610)	(119)
Net cash used in operating activities	(7,817)	(10,160)
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from the sale of equity method investment in Ascendance		354
Security deposit paid		(74)
Purchase of equipment and other	(20)	(641)
Net cash used in investing activities	(20)	(361)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from exercise of warrants		4,500
Draw down on loan facility from Juvenescence	5,700	1,800
Proceeds from Paycheck Protection Program Loan	433
Payment of debt related costs	(157)
Repayment of financing lease liability	(15)	(35)
Net cash provided by financing activities	5,961	6,265
Effect of exchange rate changes on cash, cash equivalents, and restricted cash	1	1
NET DECREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH	(1,875)	(4,255)
CASH, CASH EQUIVALENTS AND RESTRICTED CASH:
Beginning of year	2,452	6,707
End of year	577	2,452
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid during the year for interest	12	12
SUPPLEMENTAL SCHEDULE OF NONCASH FINANCING AND INVESTING ACTIVITIES:
Issuance of common stock upon vesting of restricted stock units	21
Issuance of common stock to Juvenescence (Note 4)	37	56
Issuance of warrants to Juvenescence (Note 4)	$ 1,640	$ 236